Centrient* publishes 2025 ESG Report, reinforcing its commitment to responsible and resilient manufacturing of essential medicines

• In 2025, Centrient enabled approximately 1.35 billion patient treatments worldwide, reinforcing Centrient’s role at the core of global healthcare
• Centrient achieved a 12% reduction in Scope 1 and Scope 2 emissions (vs. 2022), a 14% reduction in water withdrawal (vs. 2021), and maintained 100% compliance with AMR Industry Alliance standards to support resilient, responsible manufacturing of essential medicines
• This 2025 ESG Report is Centrient’s first report aligned with European Sustainability Reporting Standards (ESRS) under the Corporate Sustainability Reporting Directive (CSRD), marking a key milestone on its path to full CSRD compliance 

Centrient Pharmaceuticals, a global manufacturer of essential medicines, today published its 2025 Environmental, Social & Governance (ESG) Report, highlighting tangible progress in sustainable manufacturing, access to essential medicines and responsible business practices amid a rapidly changing global environment. 

As healthcare systems and customers navigate increasing complexity across supply chains, regulation and sustainability expectations, Centrient continues to invest in the capabilities that matter most: quality, reliability and operational resilience. In 2025, the company enabled approximately 1.35 billion patient treatments worldwide, supporting customers in maintaining continuity of care for patients and healthcare systems across the globe. 

“What defines us is not how we talk about ESG, but how we use it to build a more resilient business,” said Faye Freeman, CEO of Centrient. “This ESG Report shows how we are strengthening our manufacturing, reducing long-term risks and investing where it matters, so our customers and healthcare systems can count on us to deliver essential medicines, consistently and responsibly, well into the future.” 

Strong environmental progress and leadership on antimicrobial resistance (AMR) 

Centrient reported continued progress in reducing its environmental footprint. In 2025, the company achieved a 12% reduction in Scope 1 and 2 greenhouse gas (GHG) emissions compared to its 2022 base year, driven by energy efficiency improvements, increased use of greener energy sources and tighter control of refrigerant leaks (GHG emissions are calculated in accordance with the GHG Protocol using a market-based approach). Water stewardship remained a priority, particularly in water‑stressed regions, with a 14% reduction in water withdrawal compared to 2021, exceeding targets ahead of schedule. 

As a global antibiotics manufacturer, Centrient also holds a particular responsibility to address AMR. All manufacturing sites remained aligned with the AMR Industry Alliance standards, based on internal monitoring and periodic assessments, and two sites - in Spain and India, where we are the first -  received BSI Kitemark certification for minimised AMR risk – confirming Centrient’s alignment with recognised industry standards for responsible antibiotic manufacturing. 

People, communities and strong governance at the core 

On the social front, the company’s global Corporate Social Responsibility (CSR) programme positively impacted 66,602 lives worldwide through community initiatives focused on health, education, environmental stewardship and AMR awareness. 

On the governance front, Centrient continued to strengthen its global compliance framework, supported by policies, procedures and internal controls designed to ensure adherence to applicable laws and regulations. All employees formally acknowledged the Code of Conduct as of December 2025, based on internal records. 

The company maintains a speak-up mechanism that allows employees and third parties to report concerns confidentially, alongside ongoing efforts in areas such as anti-corruption, business ethics and third-party due diligence. These measures aim to support a consistent approach to responsible business conduct across Centrient’s operations and value chain. 

This report has been prepared with partial alignment to selected ESRS standards, based on the material topics identified through the Double Materiality Assessment (including ESRS 2, E1, E2, E3, E5, S1-S4 and G1). Despite ongoing regulatory uncertainty in Europe, Centrient chose to proactively publish the report as a meaningful interim milestone toward full CSRD compliance by 2028. 

Looking ahead 

While the report highlights concrete progress, Centrient remains transparent about areas where challenges remain, including renewable electricity sourcing constraints in certain regions, affecting our ambition to reach 50% renewable electricity by 2030, and the need to further advance supplier engagement on sustainable sourcing. 

Looking forward, Centrient remains focused on strengthening the systems that safeguard quality, prevent AMR, protect the environment, support its people and reinforce trust across its value chain – ensuring that resilient manufacturing continues to underpin access to essential medicines for our customers and partners worldwide.  

The Centrient ESG Report 2025 is available at www.centrient.com

*( 1) “Centrient Pharmaceuticals”, “Centrient” in this content are sometimes used for convenience where references are made to Centrient International Pharmaceuticals B.V, and or one or more of its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Centrient Pharmaceuticals International B.V. and or one or more of its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. “Subsidiaries”, “Centrient subsidiaries” and “Centrient companies” as used in this content refer to entities over which Centrient Pharmaceuticals International B.V. either directly or indirectly has control. The term “Centrient interest” is used for convenience to indicate the direct and/or indirect ownership interest held by Centrient Pharmaceuticals International B.V. in an entity or unincorporated joint arrangement, after exclusion of all third-party interest.